A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN

• Status: Withdrawn
• Trial end date: 2024-02-23
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, Phase 2 Simon 2-Stage study designed to assess the safety, tolerability, PK, and efficacy of oral zelavespib (PU-H71) administered daily in adults with accelerated phase (10% to 19% blasts in peripheral or bone marrow) myeloproliferative neoplasm, with or without ongoing concomitant treatment with ruxolitinib.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samus Therapeutics, Inc.

Criteria

Inclusion Criteria:

1. Able to provide signed informed consent and willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol

2. Aged ≥ 18 years

3. Confirmed diagnosis of accelerated phase (10% to 19% blasts in peripheral blood or bone marrow) MPN arising on the background of previous PMF, PV, or ET

4. Patients taking ruxolitinib must have been taking it for at least 3 months, with a stable dose at least 1 month before Cycle 1 Day 1

5. Eastern Cooperative Oncology Group (ECOG) performance status of 1 to 2

6. Acceptable organ function at screening, defined by the following criteria:

1. absolute neutrophil count (ANC) ≥ 500/µL

2. platelet count ≥ 50,000/µL

3. alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2 × the upper limit of normal (ULN )

4. total serum bilirubin ≤ 1.5 × ULN

5. creatinine clearance > 25 mL/min/1.73 m2 based on the Cockcroft-Gault equation

7. Women of childbearing potential (defined as premenopausal or within 2 years of the onset of menopause, and not surgically sterile) must meet both the following criteria:

1. negative urine or serum pregnancy test at screening and within 72 hours before the first dose of zelavespib

2. agree to use one of the following acceptable method of highly effective contraception for the duration of the study and for 13 weeks after the final dose of study treatment

8. Men must agree to the following requirements:

a. men who are sexually active with women of childbearing potential must agree to the following requirements for the duration of their participation in the study and for 13 weeks after the final dose of study treatment: i. if the method of contraception is abstinence from penile vaginal intercourse as a usual and preferred lifestyle (abstinent on a long-term and persistent basis), men must agree to remain abstinent ii. if having penile vaginal intercourse with a nonpregnant, non-breastfeeding woman of childbearing potential, men must use a male condom, and their female partner must use a highly effective contraceptive method with a failure rate < 1% per year iii. men with a pregnant or breastfeeding partner must agree to remain abstinent from penile vaginal intercourse or use a male condom during each episode of penile penetration iv. men must refrain from donating sperm

Exclusion Criteria:

1. Known active liver disease, including viral hepatitis or cirrhosis

2. Known or suspected infection with human immunodeficiency virus (HIV) or other active infection requiring acute or chronic treatment with systemic antibiotics (conditions requiring topical antibiotics are not exclusionary)

3. Positive for HIV 1 or 2, hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibodies at screening

4. Previous treatment with a hypomethylating agent

5. Corrected QT interval using Fridericia's formula (QTcF) > 480 ms at screening or baseline ECG based on the median value of ECGs

6. Personal or family history of long QT syndrome or taking any medication within 1 week or 5 half-lives (whichever is longer) before Cycle 1 Day 1 that carries a risk of Torsades de Pointes

7. Left ventricular ejection fraction ≤ 50% or below the institution's lower limit of normal (whichever is lower) by echocardiogram or multigated acquisition (MUGA) scan

8. Coronary artery disease with an ischemic event within 6 months before screening

9. History of a second primary malignancy within 6 months before screening that requires treatment with systemic antineoplastic agents, except for the following, if appropriately treated and considered cured: Stage 1 endometrial cancer, surgically treated cervical or prostate carcinoma, and nonmelanoma skin cancer Note: Subjects who are receiving adjuvant or preventive therapy for indolent cancers may be eligible, and the investigator should discuss with the medical monitor.

10. Any significant uncontrolled medical condition, as determined by the investigator, within 6 months before screening

11. Planned use of antineoplastic agents (chemotherapy or cytotoxic drugs), immunotherapy, experimental therapy, or biologic therapy for treatment of MPN, with the exception of ruxolitinib

12. Use of systemic corticosteroids (ie, prednisone > 20 mg/day or equivalent within 2 weeks before Cycle 1 Day 1

13. Planned or current use of strong cytochrome P450 (CYP)3A4/5, CYP2D6, or CYP2C19 inhibitors or inducers within 1 week or 5 half-lives (whichever is longer, for a maximum of 4 weeks) before Cycle 1 Day 1

14. Planned or current use of herbal preparations/medications within 7 days before Cycle 1 Day 1

15. Previous exposure to zelavespib (PU-H71)

16. Uncontrolled diabetes mellitus, in the opinion of the investigator

17. Any other condition or laboratory abnormality or receiving any other treatment that, in the opinion of the investigator, may increase the risk associated with study participation or that may interfere with interpretation of the study results

18. Active ocular condition (eg, ocular inflammatory disease that, in the opinion of the investigator, may worsen during the course of the study, or a history or anticipation of major ocular surgery (eg, cataract extraction or other intraocular surgery) during the study

19. Currently pregnant or breastfeeding, or planning to become pregnant

20. History of gastrointestinal surgery or current gastrointestinal condition that could affect the absorption of oral medication